NCT02536469View on ClinicalTrials.gov

HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Solid Tumor
Interventions
DRUG

HuMax-IL8

HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle

Trial Locations (1)

20892

National Cancer Institute, Bethesda

Sponsors
All Listed Sponsors
collaborator

This trial was conducted previously by Cormorant

UNKNOWN

lead

Bristol-Myers Squibb

INDUSTRY